🇺🇸 GLYCOPYRRONIUM in United States

6,848 US adverse-event reports

Marketing authorisation

FDA

  • Status: approved

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Death — 1,699 reports (24.81%)
  2. Dyspnoea — 1,346 reports (19.66%)
  3. Asthma — 562 reports (8.21%)
  4. Chronic Obstructive Pulmonary Disease — 540 reports (7.89%)
  5. Device Delivery System Issue — 480 reports (7.01%)
  6. Pneumonia — 452 reports (6.6%)
  7. Wheezing — 452 reports (6.6%)
  8. Cough — 444 reports (6.48%)
  9. Device Use Issue — 438 reports (6.4%)
  10. Wrong Technique In Device Usage Process — 435 reports (6.35%)

Source database →

GLYCOPYRRONIUM in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Frequently asked questions

Is GLYCOPYRRONIUM approved in United States?

Yes. FDA has authorised it.

Who is the marketing authorisation holder for GLYCOPYRRONIUM in United States?

Marketing authorisation holder not available in our data.